Universe Pharmaceuticals INC UPC
Annual
Quarterly
FY2025 · ended Sep 30, 2025 · Revenue $17.86B, -22.4% YoY · Filed Jan 29, 2026
Universe Pharmaceuticals INC (UPC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $17.9 billion and a net loss of $3.7 billion. Free cash flow was -$5.3 billion. As of Sep 30, 2025 it held $33.6 billion in cash and investments and $9.3 billion in total debt.
Revenue
$17.86B
-22.4% vs prior year
Net income
$-3.67B
+57.9% vs prior year
Operating cash flow
$-5.05B
+46.9% vs prior year
Free cash flow
$-5.32B
+45.2% vs prior year
EPS
$-8.06
+98.7% vs prior year
Dividend per share
None
Shares outstanding
563,338
-97.6% vs prior year
Net cash
$24.34B
FY 2025
Operating margin
-16.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- China
- Headquarters
- Ji'An, Jiangxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1809616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.9B | $23.0B | $32.3B | $40.1M | $48.0M |
| Operating income | -$2.9B | -$8.0B | -$4.0B | — | $13.6M |
| Net income | -$3.7B | -$8.7B | -$6.6B | -$7.9M | — |
| Diluted EPS | -$8.06 | -$626.96 | -$1,089.21 | -$1,309.11 | — |
| Operating cash flow | -$5.1B | -$9.5B | $1.1B | -$1.3M | -$2.1M |
| Free cash flow | -$5.3B | -$9.7B | $1.1B | -$1.4M | -$2.5M |
| Total assets | $69.3B | $68.0B | $41.7M | $59.5M | $70.1M |
| Total liabilities | $13.2B | $22.5B | — | — | — |
| Stockholders' equity | $56.1B | $45.5B | $28.0B | $35.3B | $47.0M |
| Cash and investments | $33.6B | $29.5B | $18.5M | $18.9M | $21.8M |
| Total debt | $9.3B | $5.9B | — | $3.9M | $4.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 6, 2026 |
| 6-K/A | Amendment no. 1 to form 6-k | Sep 3, 2026 | Sep 3, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 29, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Jun 26, 2026 | Jun 26, 2026 |
All 119 Universe Pharmaceuticals INC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.